RKTO Rocket One Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1711786 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY2.2%
TTM EPS YoY40.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-152.0%
ROA-132.9%
ROIC (approx.)-1,024.5%
Asset turnover—
Leverage & solvency
Liabilities / assets14.3%
Debt / equity0.00x
Current ratio5.55x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-10.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $35 | — | — | — | — | — | — | — |
| R&D expense | $1.12M | $1.96M | $1.52M | $1.31M | $1.63M | $1.04M | $1.96M | $1.32M |
| SG&A expense | $1.41M | $1.88M | $1.13M | $1.29M | $2.45M | $1.16M | $1.52M | $1.06M |
| Operating income | -$2.53M | -$3.83M | -$2.65M | -$2.61M | -$4.08M | -$2.20M | -$3.48M | -$2.38M |
| Pretax income | -$2.68M | -$3.83M | — | -$2.62M | -$4.11M | -$2.20M | — | — |
| Net income | -$2.68M | -$3.83M | -$2.69M | -$2.69M | -$4.11M | -$2.20M | -$3.48M | -$2.38M |
| EPS (basic) | -0.11 | -0.19 | -0.17 | — | -0.30 | -0.17 | -0.27 | — |
| EPS (diluted) | -0.11 | -0.19 | -0.17 | — | -0.30 | -0.17 | -0.27 | — |
| Weighted avg. shares (diluted) | 24.71M | 20.55M | 15.79M | — | 13.79M | 13.18M | 12.73M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $6.02M | $7.89M | $4.05M | $6.25M | $7.85M | $9.01M | $11.32M | $7.04M |
| Receivables | $4,523 | — | — | — | — | — | — | — |
| Current assets | $6.86M | $8.58M | $4.86M | $6.86M | $8.92M | $10.05M | $12.29M | $7.64M |
| Goodwill | $590,794 | — | — | — | — | — | — | — |
| Intangibles | $208,846 | — | — | — | — | — | — | — |
| Total assets | $8.66M | $9.58M | $5.59M | $7.60M | $9.24M | $10.11M | $12.36M | $7.71M |
| Current liabilities | $1.24M | $1.38M | $1.43M | $1.45M | $1.01M | $364,630 | $815,299 | $831,197 |
| Total liabilities | $1.24M | $1.38M | $1.43M | $1.45M | $1.01M | $364,630 | $815,299 | $833,906 |
| Shareholders' equity | $7.42M | $8.20M | $4.16M | $6.15M | $8.23M | $9.74M | $11.54M | $6.88M |
| Shares outstanding | 24.90M | 23.18M | 16.27M | 15.51M | 15.13M | 13.23M | 13.17M | 8.04M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.79M | -$2.97M | -$3.05M | -$2.15M | -$2.49M | -$2.37M | -$2.79M | -$2.03M |
| Investing cash flow | -$992,682 | $0 | $147,202 | $0 | — | — | — | — |
| Financing cash flow | $1.90M | $6.81M | $701,484 | $550,138 | $1.63M | $66,101 | $7.07M | $1.06M |
| Stock-based compensation | $123,137 | $677,079 | $0 | $0 | $1.13M | $55,525 | $219,929 | $541 |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.